January 6, 2025
Photo provided by CooperVision
FAREHAM, U.K. — CooperVision has announced a new myopia control contact lens, the MyDay MiSight 1 day contact lenses. The new myopia treatment will be launching in the U.K. and select European and surrounding markets, expanding the company’s evidence-based myopia management portfolio. This new myopia control soft contact lens combines the proven MiSight 1 day ActivControl Technology with the advanced silicone hydrogel material used in MyDay lenses.*1
“Our commitment to tackling myopia—both scientifically and commercially—has been unwavering,” said Debbie Olive, Chief Commercial Officer for CooperVision. “With MyDay MiSight 1 day, we’ve applied the advanced silicone hydrogel material found in our MyDay contact lenses*1 while harnessing the life-changing potential of myopia control.”†2,3,4
The company’s ActivControl Technology has demonstrated an approximate 50% reduction in myopia progression†2,3 and is backed by the longest-running soft contact lens clinical trial among children.§ Hundreds of thousands of children globally now wear contact lenses featuring this technology.5 The lens design incorporates vision correction zones and treatment zones to provide clear vision while helping to control the worsening of myopia.à6-8
“This innovation delivers ‘always-on’ myopia control—children benefit from treatment throughout the day, simply by wearing their contact lenses,” said Jennifer Lambert, Vice President, Myopia Management and Cornea Care, CooperVision.¶9-11 “It’s also designed to help support a smooth transition from myopia management to adult lens wear, thanks to its shared material and specifications with MyDay lenses.”**
At launch in the U.K. and select European and surrounding markets, the product will be available in the following parameters:
| Sphere Power Range | Step Size |
| -0.25 to -6.00 | 0.25D |
| -6.50 to -10.00 | 0.50D |
To learn more about this innovation and CooperVision’s evidence-based myopia management portfolio, visit www.coopervision.co.uk.
References
* Proven to slow myopia progression in children compared to a single vision 1-day lens over a three-year period.
† Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight 1 day, which shares the same ActivControl Technology with MyDay MiSight 1 day
‡ Proven to slow myopia progression in children compared to a single vision 1-day lens over a three-year period.
§ MyDay MiSight 1 day contact lenses use the same ActivControl Technology as the original MiSight 1 day.
à MyDay MiSight 1 day contact lenses use the same ActivControl Technology as the original MiSight 1 day.
¶ In clinical study, mean weekday wear time increased from 12.8 hours/day at six-months to 13.9 hours/day at six-years with a mean of >6.5 days/week for MiSight 1 day, which shares the same ActivControl Technology with MyDay MiSight 1 day.
** MyDay daily disposable and MyDay Energys.
1 Chamberlain P et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567
2 Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
3 CVI data on file, 2025
4 Vision standards and requirements. Association of Optometrists. (n.d.). Retrieved December 20, 2021, from https://www.aop.org.uk/advice-
5 CVI data on file 2025. Internal global wearer modeling estimates for the 12-month period of October 2024 to September 2025
6 Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. OVS 2019; 96(8):556-567. –
7 CVI data on file, 2025. Prospective, 1-week, double masked, bilateral study with MiSight 1 day silicone hydrogel. N=32 subjects aged 8-18 years. –
8 CVI data on file, 2025
9 Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391. –
10 CVI data on file, 2025. Prospective, 1-week, double masked, bilateral study with MiSight 1 day silicone hydrogel. N=32 subjects aged 8-18 years. –
11 CVI data on file, 2025
